CD44 and urinary bladder carcinoma: Li et al. combined the uses of human bladder cancer cell monoclonal antibody BCMab1 and anti-CD44 antibody which specifically recognize bladder cancer marker AG-α3β1, and successfully isolated a subgroup of cells with stem cell characteristics (BCMab1+/CD44+ subgroup).